FreeOx Biotech has been selected for two first level programmes of EIT Health, a network of more than 140 member universities and companies which innovate in healthcare supported by the European Institute of Innovation and Technology (EIT) of the European Commission.
Specifically, FreeOx is one of the 15 winning start-ups of the Headstart Funding programme of EIT Health Spain which awards subsidies to early-stage companies which develop healthcare products or services with a clear market orientation. FreeOx will receive a grant of approximately 30,000 Euros.
Additionally, FreeOx has been selected to participate in the semifinals of European Health Catapult which EIT Health is organising from 24 to 26 September in Leuven (Belgium). Carlos Lurigados, co-founder and CEO of the company, will be present at the event. The company presentation will take place during the EIT Health Investors Forum.
The European Health Catapult is a training and competition platform for start-ups or young SMEs in Medtech, Biotech and Digital Health. Besides the chance to win a total prize money at the EIT Health Summit, accepted companies will have the possibility to mature their business plan, negotiation and pitching skills as well as to learn from experts during training days with other startups from all over Europe.
FreeOX, a spin-out of Hospital Clinic Barcelona–IDIBAPS founded in 2017, has two molecules in their pipeline: Ox-01, a powerful anti-oxidant drug that has completed phase IIb with promising results for stroke (a disease that is very much in need of therapeutic options) among other diseases of the central nervous system, and Ox-02, a molecule resulting from the association of Ox-01 and citicoline in preclinical stage.
